Widespread implementation of cytology-based screening programs has resulted in marked declines in cervical cancer incidence and mortality in the United States. Nonetheless, an estimated 13 240 women will be diagnosed with cervical cancer in 2018, and 4170 will die from the disease.1 It is likely that a sizable proportion of these women will not have been appropriately screened.2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Sawaya GF. Cervical Cancer Screening—Moving From the Value of Evidence to the Evidence of Value. JAMA Intern Med. 2018;178(10):1293–1295. doi:10.1001/jamainternmed.2018.4282
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: